NSG 318 Topic 1 pharmacokinetics application paper example

Introduction to Pharmacology Grand Canyon University Free custom sample in 24 to 48h

This NSG 318 Topic 1 sample paper applies pharmacokinetics at the bedside to explain why glyburide is riskier for Mrs. P., a composite 83-year-old with low albumin and reduced kidney function. It was written for GCU NSG 318, Introduction to Pharmacology, catalog code NSG-318, a course in Grand Canyon University's BSN. Absorption, distribution, metabolism and excretion are taken in turn. Low albumin raises the free fraction of a highly protein-bound drug. Slower hepatic metabolism and an eGFR of 34 let active metabolites accumulate. Half-life explains when harm peaks. The AGS Beers Criteria and ADA standards support the concern, and nursing actions follow from Burchum and Rosenthal.

CourseNSG 318 Introduction to Pharmacology
TopicTopic 1
Paper typePharmacokinetics application paper
LengthAbout 950 words, 3 pages
FormatAPA 7 student paper
SchoolGrand Canyon University (GCU)
ProgramBSN
UpdatedOctober 2026

Free sample paper for NSG 318 Topic 1

1

Pharmacokinetics at the Bedside: Why Glyburide Is Riskier for an 83-Year-Old Woman With Low Albumin and Reduced Kidney Function

[Author Name]

College of Nursing and Health Care Professions, Grand Canyon University

NSG-318: Introduction to Pharmacology

Topic 1 Assignment

[Instructor Name]

September 7, 2026

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

What this page is doingThe title names one drug, one patient and the two physiological changes that alter how the drug behaves in her body. A pharmacokinetics paper earns credit by applying absorption, distribution, metabolism and excretion to a real patient, so the title promises application rather than definitions. The patient is a composite.
2

Pharmacokinetics at the Bedside: Why Glyburide Is Riskier for an 83-Year-Old Woman With Low Albumin and Reduced Kidney Function

The Patient and the Drug

Mrs. L. P., 83, a composite patient, lives in an assisted living facility. She has type 2 diabetes, chronic kidney disease, her filtration rate most recently estimated at 34 mL/min/1.73 m2, and recent weight loss; her serum albumin is 2.9 g/dL, below the usual range of about 3.5 to 5.0. At a clinic visit her A1C was 8.4 percent, and a new prescriber started glyburide 5 milligrams each morning. Glyburide is a sulfonylurea that stimulates insulin release from the pancreas. It is highly bound to plasma proteins, largely albumin, and is metabolized in the liver to metabolites, some of which retain glucose-lowering activity and are eliminated partly by the kidneys (Burchum & Rosenthal, 2022). Each of the four phases of pharmacokinetics changes how this drug will behave in her, and each points to something the nurse must watch.

Absorption

Glyburide is taken by mouth and absorbed from the small intestine. Taking it with breakfast is standard, and food can delay the time to peak concentration, so the strongest glucose-lowering effect may come a few hours after the meal rather than with it. For Mrs. P., whose intake at the facility is irregular, absorption timing matters practically: if she takes the tablet with breakfast and then eats little at lunch, the drug's peak effect will arrive when there is little food to balance it. The nurse needs to know what she actually ate, not only that a meal was served.

Distribution

Only the unbound, or free, fraction of a drug can leave the bloodstream, reach its site of action and exert an effect. A drug that is highly protein bound normally has a small free fraction, with the bound drug acting as a reservoir. When albumin is low, fewer binding sites are available, so a larger proportion of each dose circulates free. For Mrs. P., a standard dose of a highly protein-bound drug may behave like a larger dose, because more of it is free to act. That increases the chance of hypoglycemia, which in an 83-year-old may show up not as sweating and shakiness but as confusion, falls or unusual sleepiness that staff could mistake for her usual fatigue.

What this page is doingThe patient, drug and physiological changes are set out first, so each phase can be applied to her. Absorption is tied to the timing of meals she actually eats, and distribution explains why low albumin leaves more free drug circulating. The highlighted sentence states the clinical consequence plainly, and the paragraph ends with what the nurse would actually see.
3

Metabolism

Glyburide is metabolized by the liver. In older adults, hepatic blood flow and some enzyme activity decline with age, so metabolism may be slower and the drug may last longer. Of more concern here, the liver converts glyburide into metabolites that still lower blood glucose. Those active metabolites must then be excreted, which brings the kidneys into the picture.

Excretion

The active metabolites of glyburide are eliminated partly through the kidneys. With an estimated glomerular filtration rate of 34, Mrs. P.'s kidneys clear them more slowly, so they accumulate with repeated doses, prolonging and intensifying the glucose-lowering effect. The combination of a larger free fraction from low albumin, possibly slower hepatic metabolism, and accumulation of active metabolites from reduced kidney function creates a high risk of prolonged, severe hypoglycemia. For this reason, the American Geriatrics Society Beers Criteria advise avoiding glyburide in older adults and favoring alternatives with a lower risk of hypoglycemia (American Geriatrics Society Beers Criteria Update Expert Panel, 2023).

Half-Life, Accumulation and Timing of Harm

The four phases combine to change when harm is most likely. A drug reaches a steady concentration after about four to five half-lives of regular dosing. When elimination slows, as it does here through reduced kidney clearance of active metabolites, the effective half-life lengthens, so steady state takes longer to reach and settles at a higher level. In practice this means the first dose may seem well tolerated, and the danger may appear several days later, as the drug and its metabolites build up. A nurse who checks blood glucose carefully on day one and then relaxes will miss the period of greatest risk. The same reasoning explains why hypoglycemia from a long-acting sulfonylurea in an older adult can recur for many hours after treatment with juice or glucose gel: the drug is still being released from its reservoir and cleared slowly. A patient treated for a low at 1400 needs rechecks through the evening, not a single follow-up value.

Pharmacokinetics also explains why a lower dose of the same drug is not a complete answer. Halving the dose reduces the amount of drug but does not fix the slower clearance of its active metabolites or the higher free fraction from low albumin. For a patient with all three changes, a different drug is usually a safer choice than a smaller dose of this one.

What the Nurse Watches For and Does

The pharmacokinetic reasoning translates into specific nursing actions. The nurse checks capillary glucose before breakfast and in the late morning and mid-afternoon for the first week, since the peak effect and accumulation make daytime lows likely. She asks facility staff to report any new confusion, falls, unusual sleepiness or skipped meals, and teaches them that these can be signs of low blood sugar in an older adult. She ensures that glucose gel or juice is available and that staff know the facility's hypoglycemia protocol. And because the evidence and guidelines point away from this drug for a patient like Mrs. P., the nurse raises the prescription with the provider, citing her age, albumin and kidney function, and asks whether a drug with lower hypoglycemia risk could be used. Current diabetes standards for older adults emphasize avoiding hypoglycemia and relaxing glycemic targets for people at higher risk (American Diabetes Association Professional Practice Committee, 2024). Questioning the choice is not overstepping; it is the nurse applying pharmacokinetics to protect a patient.

References

American Diabetes Association Professional Practice Committee. (2024). 13. Older adults: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S244-S257. https://doi.org/10.2337/dc24-S013

American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372

Burchum, J. R., & Rosenthal, L. D. (2022). Lehne's pharmacology for nursing care (11th ed.). Elsevier.

Reading the GCU NSG 318 Topic 1 instructions

Topic 1 in NSG-318 asks students to apply pharmacokinetic principles to a drug and a patient. Strong papers take absorption, distribution, metabolism and excretion in turn and explain how each is changed by this patient's characteristics, such as age, albumin level or kidney function, rather than defining the phases in general. Students should connect the phases to half-life and accumulation to explain when harm is most likely, cite authoritative sources such as the course text and the Beers Criteria and translate the reasoning into specific nursing actions, such as timed glucose checks. Enough pharmacokinetics to explain the patient's risk is expected, not a full pharmacology review.

How this NSG 318 Topic 1 example is built

Four linked sections make up the finished paper. It begins with a composite older adult who has a low serum albumin, reduced kidney function and a new prescription for a drug that is heavily protein bound and cleared by the kidneys. Absorption is discussed through route and timing, including why an oral dose taken with a meal may peak later. Distribution explains why low albumin leaves more free drug circulating, and what that means for the sedation or bleeding the nurse watches for. Metabolism covers the first-pass effect in plain terms, which is why oral and intravenous doses of one drug differ. Excretion connects half-life and renal function to the timing of monitoring. Every phase closes on a sentence naming the nursing check it produces, and no drug name or dose is offered as a recommendation.

Reading the NSG 318 Topic 1 rubric

Faculty reward the four phases applied to one patient. An Excellent paper explains that low albumin raises glyburide's free fraction and that an eGFR of 34 lets active metabolites accumulate. Credit goes to slower hepatic metabolism in older adults and to half-life explaining why hypoglycemia peaks days after a dose change, with Burchum and Rosenthal. The rubric values citing the AGS Beers Criteria, which advise avoiding glyburide in older adults, and ADA standards. The best papers end with timed glucose checks before breakfast, in late morning and mid-afternoon.

Common NSG 318 Topic 1 mistakes, and how to avoid them

Most marks on this topic are lost to definitions that never leave the textbook. A paper that explains absorption, distribution, metabolism and excretion correctly, and then stops, shows the terms were learned without showing why a nurse needs them, and the application criterion stays thin. Another frequent deduction comes from treating the patient as average, since the course expects age, albumin and kidney function to change the reasoning. Writers also lose credit for describing half-life without connecting it to when anything is checked, which leaves the monitoring half of the paper empty. Confusing first-pass metabolism with excretion is a factual error graders catch quickly, and uncited physiology costs a steady amount in any section. Papers scored highest let one abnormal laboratory value alter what the nurse does, and they say so in a plain sentence.

Get an NSG-318 Topic 1 example written to your instructions

Send the NSG-318 Topic 1 instructions and rubric from your classroom, along with any case or drug the prompt names. We write a custom example to those criteria, using a composite patient and illustrative values only, and return it in 24 to 48 hours. The first one is free. Nothing in it is guidance for giving a real medication.

More NSG 318 papers and BSN samples

NSG 318 Topic 1 questions, answered

How much pharmacokinetics does a nursing course expect?

Enough to change an action. Most introductory sections want the four phases understood well enough to explain why a patient's age, liver, kidneys or albumin alter a drug's effect, and what that means for assessment and monitoring. Rate constants and formulas are usually left to pharmacy programs. Check your syllabus, since some instructors add a short half-life calculation, and any figures in the example are illustrative.

Should the paper name a specific drug?

Follow the prompt. Many sections supply one; when the choice is open, a drug with a well-known protein binding or renal clearance profile makes the phases easier to show. The example keeps the patient composite and presents every number as illustrative, since the paper demonstrates reasoning about how drugs move through the body rather than recommending anything for a real person.

What sources work for this topic?

Your course pharmacology textbook first, then a current drug reference for anything specific about the agent, both cited in APA. General health websites rarely describe protein binding or clearance precisely enough to support a claim. LopesWrite compares each submission against published material, so a sentence taken from a drug reference is flagged like any other borrowed wording unless it is quoted and cited.

Where can I find a free NSG 318 Topic 1 sample paper?

The pharmacokinetics paper for NSG 318 Topic 1 covers the patient and the drug, absorption, distribution, metabolism, excretion, half-life and timing of harm and what the nurse watches for and does. Send your NSG 318 Topic 1 prompt and a paper follows free.

Why does low albumin matter in NSG 318 Topic 1?

Glyburide is highly protein bound, and only the free drug acts. With less albumin to bind it, more glyburide is free, which strengthens its glucose-lowering effect.